Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felice Musicco

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy surveyPeter J Gilbar, Carole R Chambers, Felice Musicco
European Journal of Clinical Pharmacology|January 9, 2019
Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in EuropeRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
European Journal of Clinical Pharmacology|March 4, 2020
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trialsRuggero Lasala, Andrea Logreco, Alessia Romagnoli, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 21, 2022
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugsRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Current Medical Research and Opinion|March 18, 2023
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overviewRuggero Lasala, Andrea Zovi, Valentina Isgrò, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2021
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinomaRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Recenti Progressi in Medicina|November 17, 2024
Felice Musicco, Ruggero Lasala, Fiorenzo Santoleri, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 25, 2021
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016Ruggero Lasala, Fiorenzo Santoleri, Davide Zanon, et al.
Life Sciences|November 25, 2019
Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challengesRita S Moreira, Joana Bicker, Felice Musicco, et al.
Recenti Progressi in Medicina|December 20, 2021
[Immunotherapy with nivolumab and pembrolizumab in unresectable or metastatic advanced melanoma: real-life observational study of drug use.]Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 17, 2021
Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy surveyPeter J Gilbar, Carole R Chambers, Felice Musicco
European Journal of Clinical Pharmacology|January 9, 2019
Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in EuropeRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
European Journal of Clinical Pharmacology|March 4, 2020
Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trialsRuggero Lasala, Andrea Logreco, Alessia Romagnoli, et al.
European Journal of Hospital Pharmacy : Science and Practice|January 21, 2022
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugsRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Current Medical Research and Opinion|March 18, 2023
Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overviewRuggero Lasala, Andrea Zovi, Valentina Isgrò, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2021
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinomaRuggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, et al.
Recenti Progressi in Medicina|November 17, 2024
Felice Musicco, Ruggero Lasala, Fiorenzo Santoleri, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 25, 2021
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016Ruggero Lasala, Fiorenzo Santoleri, Davide Zanon, et al.
Life Sciences|November 25, 2019
Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challengesRita S Moreira, Joana Bicker, Felice Musicco, et al.
Recenti Progressi in Medicina|December 20, 2021
[Immunotherapy with nivolumab and pembrolizumab in unresectable or metastatic advanced melanoma: real-life observational study of drug use.]Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, et al.
Pageof 3